Title

Safety, pharmacokinetics and acceptability of PC-1005 for vaginal use

Document Type

Registered Trial

Publication Date

2015

Abstract

This Phase 1 clinical trial will evaluate MIV-150, a third generation non-nucleoside reverse transcriptase inhibitor, co-formulated with a potentially potent agent, zinc acetate for the prevention of HIV infection in women. This is the first in-human of PC-1005 (MIV-150/zinc acetate in a carrageenan gel), the first study in which females will be exposed to MIV-150, the first time MIV-150 will be administered topically, and the first time MIV-150 will be administered intravaginally.

DOI

ClinicalTrials.gov Identifier: NCT02033109

Language

English

Share

COinS